Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide 2.4 mg for low responders after bariatric surgery (SEABAR)
2022-502164-20-01Phase 4Authorised
- Sponsor
- Zuyderland
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of semaglutide in obesity, sponsored by Zuyderland. Planned start Sep 2024; status: authorised.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on 2022-502164-20-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502164-20-01.